Clinical Trial Update: Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of nivolumab for recurrent/metastatic olfactory neuroblastoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Olfactory Neuroblastoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Recurrent/ Metastatic Olfactory Neuroblastoma | Phase 2 | Status: RECRUITING